Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07369024 · ClinicalTrials.gov registry record · Phase 2
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
A Phase 2 study of Sickle Cell Disease and Pain Management, sponsored by Mohsen Saidinejad.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07369024 is a Phase 2 study of Sickle Cell Disease and Pain Management that is actively recruiting participants, run by Mohsen Saidinejad. The registered enrollment target is 120 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07369024, a Phase 2 study of Sickle Cell Disease and Pain Management, is actively recruiting participants, sponsored by Mohsen Saidinejad.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.
Conditions Studied
Interventions
- DRUG Sub-dissociative Ketamine Infusion
- DRUG Normal Saline Placebo Infusion
Study Locations (1)
California
- Harbor UCLA Medical Center - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07369024
The ClinicalTrials.gov registry entry for NCT07369024 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (59% lower). The listed sponsor is Mohsen Saidinejad, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Sub-dissociative Ketamine Infusion is the first listed.
NCT07369024 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07369024 about?
NCT07369024 is a clinical study titled "Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults". The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an o...
What is the current status of trial NCT07369024?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-04-01. Estimated completion is 2028-04-30.
What conditions does trial NCT07369024 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Pain Management, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Vaso-Occlusive Crises.
What interventions are being tested in trial NCT07369024?
The interventions under investigation include: Sub-dissociative Ketamine Infusion (DRUG), Normal Saline Placebo Infusion (DRUG).
Who is sponsoring clinical trial NCT07369024?
This trial is sponsored by Mohsen Saidinejad, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07369024 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
-
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.